Firebrick Pharma (ASX:FRE) is preparing for a pivotal year in 2026 as it accelerates the commercial expansion of its Nasodine product portfolio and pushes into new international markets.
The company, which develops antimicrobial treatments based on povidone iodine, believes the coming year will mark the transition of its flagship nasal spray from early adoption into a sustained growth phase.
Nasodine Nasal Spray has already begun gaining momentum in the United States and Singapore, where recent winter demand drove a sharp rise in online sales. During the December 2025 to February 2026 period in the United States, sales increased by 275 per cent compared with the previous winter, while the number of customers purchasing the product online rose by 168 per cent. Singapore also experienced strong seasonal demand, with winter sales rising by more than 200 per cent. On the back of this surge, the company expects overall sales to at least double during 2026.
A key driver of this growth will be the expansion of the Nasodine product range. In early 2026, the company began launching Nasodine Throat Spray, a follow-on product designed to protect against and treat sore throats. The product has already launched online in Singapore and begun promotion to healthcare professionals and hospitals, while Fiji has started its own rollout through pharmacies and clinicians. A United States online launch is expected later in the year, potentially opening a much larger market for the new product.
Firebrick also plans to introduce a third Nasodine product during 2026, expanding the portfolio beyond nasal and throat sprays. This broader product range is expected to strengthen the Nasodine brand and create a portfolio effect in which demand for one product helps drive awareness and sales of the others.
Geographic expansion will be another central focus of the year. The company is pursuing regulatory approval for Nasodine Nasal Spray in the Philippines, one of Southeast Asia’s largest healthcare markets, while approvals in two additional countries in the region are also anticipated. These approvals would extend the brand’s reach beyond its current markets in the United States, Singapore and Fiji, laying the groundwork for a much larger regional presence.
Behind this expansion is a licensing model designed to scale globally with limited operating costs. Firebrick develops the products and licenses distribution rights to regional partners, who handle regulatory approvals and fund marketing in their territories. In return, Firebrick receives margins and royalties on sales, typically generating around two to three Australian dollars per unit. The company believes this structure could enable it to become profitable once annual sales reach one million units.